Immunotherapeutic approaches for fungal infections.
Journal
Current opinion in microbiology
ISSN: 1879-0364
Titre abrégé: Curr Opin Microbiol
Pays: England
ID NLM: 9815056
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
31
03
2020
revised:
25
08
2020
accepted:
15
09
2020
pubmed:
5
11
2020
medline:
25
5
2021
entrez:
4
11
2020
Statut:
ppublish
Résumé
Despite the availability of antifungal treatments, fungal infections are still causing morbidity all around the globe with unacceptably high mortality rates. A major driver for the rising incidence of serious fungal infections is due to a substantial increase in immunocompromised individuals with autoimmune diseases, cancers and transplants. Because of growing resistance in fungus to frontline triazole antifungals and the association of fungal disease with the immunocompromised host, adjunctive host-directed therapy is seen as a promising choice to improve patient outcomes. Immunotherapeutic treatments being explored as adjunct therapies to existing antifungal treatments include cytokine therapy, monoclonal antibodies and cellular immunotherapy. In this review, we give a brief overview of potential immunotherapies and recent developments in the field, which are needed to tackle the growing problem of fungal diseases.
Identifiants
pubmed: 33147544
pii: S1369-5274(20)30111-9
doi: 10.1016/j.mib.2020.09.007
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
130-137Subventions
Organisme : Medical Research Council
ID : MR/P028225/1
Pays : United Kingdom
Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.